Developmental Expression of the Major Human Hepatic CYP3A Enzymes

The human cytochrome P4503A forms show expression patterns subject to developmental influence. CYP3A7 and CYP3A4 are generally classified as the major fetal and adult liver forms, respectively. However, characterization of CYP3A4, -3A5, and -3A7 developmental expression has historically been confounded by the lack of CYP3A isoform-specific antibodies or marker enzyme activities. Therefore, the objective of this study was to characterize the developmental expression of hepatic CYP3A forms from early gestation to 18 years of age using up to 212 fetal and pediatric liver samples. Based on immunoquantitation, CYP3A5 protein expression was found to be highly variable, generally independent of age, and more frequently observed for African-American individuals. For differentiation of CYP3A4 and -3A7 levels, dehydroepiandrosterone metabolite patterns for expressed CYP3A forms were characterized and used for simultaneous quantitation of protein levels within liver microsome samples. The major metabolite formed by CYP3A4, 7β-hydroxy-dehydroepiandrosterone, was identified based on cochromatography and mass spectra matching with the authentic standard. Kinetic analysis showed a 34-fold greater intrinsic clearance of 7β-hydroxy-dehydroepiandrosterone by CYP3A4 versus -3A7, whereas CYP3A7 showed the highest 16α-hydroxy-dehydroepiandrosterone intrinsic clearance. Metabolite profiles for the expressed enzymes were fit to a multiple response model and CYP3A4 and -3A7 levels in fetal and pediatric liver microsome samples were calculated. Fetal liver microsomes showed extremely high CYP3A7 levels (311-158 pmol/mg protein) and significant expression through 6 months postnatal age. Low CYP3A4 expression was noted for fetal liver (≤10 pmol/mg), with mean levels increasing with postnatal age.

[1]  W. Pierce,et al.  Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions. , 2001, Archives of biochemistry and biophysics.

[2]  N. Cheung,et al.  Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. , 1996, The Journal of clinical endocrinology and metabolism.

[3]  R. Edwards,et al.  Cytochrome P450 3A Expression in the Human Fetal Liver: Evidence that CYP3A5 Is Expressed in Only a Limited Number of Fetal Livers , 2001, Neonatology.

[4]  F. Guengerich Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. , 1983, Biochemistry.

[5]  M. Relling,et al.  Human cytochrome P450 maximal activities in pediatric versus adult liver. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[6]  G. Kearns,et al.  Cytochrome P450 3A , 1999, Clinical pharmacokinetics.

[7]  G. Chabot,et al.  Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. , 2002, Biochemical pharmacology.

[8]  L Hendeles,et al.  Theophylline A “State of the Art” Review , 1983, Pharmacotherapy.

[9]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[10]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[11]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[12]  L. Wienkers,et al.  Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[13]  D. Greenblatt,et al.  Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.

[14]  J. George,et al.  Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. , 1998, The Journal of clinical endocrinology and metabolism.

[15]  S. Hirschfeld Dysregulation of growth and development in HIV-infected children. , 1996, The Journal of nutrition.

[16]  G. Kearns,et al.  The challenges of delivering pharmacogenomics into clinical pediatrics , 2002, The Pharmacogenomics Journal.

[17]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[18]  H. Glaeser,et al.  Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine* , 2002, The Journal of Biological Chemistry.

[19]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[20]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[21]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[23]  J. Magny,et al.  Population pharmacokinetics of midazolam in neonates , 1994, Clinical pharmacology and therapeutics.

[24]  P. Watkins,et al.  THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.

[25]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[26]  T. Shimada,et al.  Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[27]  S. Imaoka,et al.  A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. , 1997, Life sciences.

[28]  A. Berkenstam,et al.  Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. , 2001, Biochemical and biophysical research communications.

[29]  H. Yamazaki,et al.  Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[30]  J. Brockmöller,et al.  Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[31]  E. Schuetz,et al.  Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo , 2003, Clinical pharmacology and therapeutics.

[32]  H. Yamazaki,et al.  Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. , 2002, Protein expression and purification.

[33]  S. Yamaguchi,et al.  No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. , 1999, Biochemical pharmacology.

[34]  S. Wrighton,et al.  Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. , 1989, Archives of biochemistry and biophysics.

[35]  A. Rettie,et al.  Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression , 2002, Pediatric Research.

[36]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[37]  T. Kamataki,et al.  P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate. , 1987, The Journal of biological chemistry.

[38]  T. Cresteil,et al.  Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.

[39]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.